Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511561 · ClinicalTrials.gov registry record · Phase 2
OTO-201 for the Treatment of Otitis Externa
A Phase 2 study of Otitis Externa, sponsored by Otonomy.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT02511561 is a Phase 2 study of Otitis Externa that has completed, run by Otonomy. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02511561, a Phase 2 study of Otitis Externa, has completed, sponsored by Otonomy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa. Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with otitis externa.
Conditions Studied
Interventions
- DRUG OTO-201 (ciprofloxacin)
Study Locations (1)
California
- Email Otonomy Central Contact for Trial Locations - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02511561
The ClinicalTrials.gov registry entry for NCT02511561 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otonomy, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Otitis Externa appearing as the primary indexed condition, and to 1 intervention - of which OTO-201 (ciprofloxacin) is the first listed.
NCT02511561 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02511561 about?
NCT02511561 is a clinical study titled "OTO-201 for the Treatment of Otitis Externa". This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa. Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with...
What is the current status of trial NCT02511561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2015-07. Estimated completion is 2015-11.
What conditions does trial NCT02511561 study?
This clinical trial studies the following conditions: Otitis Externa.
What interventions are being tested in trial NCT02511561?
The interventions under investigation include: OTO-201 (ciprofloxacin) (DRUG).
Who is sponsoring clinical trial NCT02511561?
This trial is sponsored by Otonomy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02511561 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.